Objective: The mechanisms of action of arsenic in the development of lung cancer are still not yet elucidated. Considering the relationship between arsenic and squamous cell carcinomas of the skin, we hypothesized that arsenic exposure may be more closely associated with squamous cell carcinoma of the lung.
Methods: A comprehensive histopathological database and a detailed job-exposure matrix developed for former German uranium miners with exposure to arsenic, radon, and quartz were analyzed to quantitatively assess the effect of arsenic regarding cell type of lung cancer. The distributions of major lung cancer cell types in 1,786 German uranium miners were associated with levels of arsenic exposure under control for the other lung carcinogens. To evaluate the arsenic effects in association with a frequent occupational lung disease in miners stratification by silicosis was performed.
Results: There was an arsenic-related increase of the proportion of squamous cell carcinoma of the lung but restricted to miners without silicosis. The increase was found at all levels of co-exposure to radon and quartz dust. In miners with silicosis, the proportion of adenocarcinoma increased with rising arsenic exposure. Arsenic exposure was associated with non-small cell lung cancer. Silicosis turned out as major determinant of the cell type related with arsenic.
Conclusion: These results indicate a cell type characteristic effect of arsenic in the development of lung cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00420-008-0386-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
CRISPR/Cas13a-Programmed Cu NCs and -Scheme T-COF/AgS for Photoelectrochemical Biosensing of circRNA.
ACS Sens
January 2025
College of Public Health, Zhengzhou University, Zhengzhou 450001, China.
Circular RNAs (circRNAs), as a class of noncoding RNA molecules with a circular structure exhibit high stability and spatiotemporal-specific expression, making them ideal cancer biomarkers for liquid biopsy. Herein, a new photoelectrochemical (PEC) biosensor for a highly sensitive circRNA assay in the whole blood of lung cancer patients was designed based on CRISPR/Cas13a-programmed Cu nanoclusters (Cu NCs) and a -scheme covalent organic framework/silver sulfide (T-COF/AgS) composite. This -scheme T-COF/AgS composite accelerates electron transfer and produces an excellent initial photocurrent.
View Article and Find Full Text PDFSuccessful Diagnosis of a SMARCA4-Deficient Undifferentiated Tumor via Endobronchial Ultrasound-Guided Fine Needle Aspiration and Endobronchial Biopsies.
Cureus
December 2024
Pulmonary and Critical Care, Brody School of Medicine, East Carolina University, Greenville, USA.
Lung cancer is the third most prevalent cancer, following breast cancer in women and prostate cancer in men. However, it remains the leading cause of cancer-related mortality. As treatment options have advanced, the significance of accurate diagnosis has increased, enabling targeted and more personalized therapeutic treatments.
View Article and Find Full Text PDFCase report: Relapse of intrathyroidal parathyroid carcinoma in a patient with novel variants in and genes.
Front Oncol
January 2025
Administration, Endocrinology Research Center, Moscow, Russia.
Parathyroid carcinoma (PC) is one of the rarest malignant neoplasms of the human endocrine system, with a prevalence of approximately 0.005% of all oncological diseases. Despite its indolent course, PC generally relapses in about 40%-60% of cases.
View Article and Find Full Text PDFGlobalisation of industry-sponsored clinical trials for breast, lung and colon cancer research: trends, threats and opportunities.
BMJ Oncol
September 2023
Department of Public Health, Institute of Tropical Medicine, Antwerpen, Belgium.
Objective: Breast, lung, colon cancers are the 'big killers' in oncology. Access to innovative treatments lags behind in low-income and middle-income countries. We investigated the geographic distribution of industry-sponsored trials; and whether results were reported in clinical trial registries.
View Article and Find Full Text PDFGlobal trends in incidence, death, burden and risk factors of early-onset cancer from 1990 to 2019.
BMJ Oncol
September 2023
Department of Big Data in Health Science, School of Public Health and The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Objective: This study aimed to explore the global burden of early-onset cancer based on the Global Burden of Disease (GBD) 2019 study for 29 cancers worldwid.
Methods And Analysis: Incidence, deaths, disability-adjusted life years (DALYs) and risk factors for 29 early-onset cancer groups were obtained from GBD.
Results: Global incidence of early-onset cancer increased by 79.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!